The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...

Although Novo was first to market with Wegovy and its sister ... The company is also studying Zepbound’s impact on illness and death in a trial that’s due to deliver results in 2027.

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...